Historical record - last NADAC effective date: 5/22/2024
Product Information
DOXEPIN 75 MG CAPSULE is a generic product labeled by Leading Pharma, LLC, priced at $0.2243 per EA under NDC 69315016101. Its NADAC has been published 49 times since Jun 28, 2023.
FDA first approved this application on Mar 9, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
75 mg/1
Manufacturer
Leading Pharma, LLCNDC
69315016101
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
5/22/2024
Active Ingredients
DOXEPIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA211619FDA Approved
3/9/2021
TE Code
AB
On Market Since
4/15/2021
Pharmacological Classes
Price Statistics
The NADAC for DOXEPIN 75 MG CAPSULE has been published 49 times since Jun 28, 2023, and over the history we have for it it has declined 16.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2243 per EA |
|---|---|
| All-time high | $0.4253 (Dec 13, 2023) |
| All-time low | $0.2243 (May 22, 2024) |
| Median price | $0.3282 |
| Average price | $0.3179 |
| Largest weekly change | +46.9% (Jul 19, 2023) |
| Weeks tracked | 49 |
| Tracking since | Jun 28, 2023 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-10.6%
5Y
N/A
All
-16.9%
Last surveyed May 29, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Leading Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DOXEPIN HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXEPIN 75 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DOXEPIN 75 MG CAPSULE, manufactured by Leading Pharma, LLC, is $0.2243 per EA (NDC 69315016101), effective May 29, 2024.
How has the price of DOXEPIN 75 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DOXEPIN 75 MG CAPSULE has declined 16.9%. It has been tracked across 49 weekly CMS publications since Jun 28, 2023.
What are the highest and lowest recorded NADAC prices for DOXEPIN 75 MG CAPSULE?
Since Jun 28, 2023, the NADAC for DOXEPIN 75 MG CAPSULE has ranged from a low of $0.2243 (May 22, 2024) to a high of $0.4253 (Dec 13, 2023), with a median of $0.3282 per EA.
Are there cheaper alternatives to DOXEPIN 75 MG CAPSULE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DOXEPIN 75 MG CAPSULE, is $0.1966 per EA — about 12% below DOXEPIN 75 MG CAPSULE.
Who manufactures DOXEPIN 75 MG CAPSULE?
DOXEPIN 75 MG CAPSULE (NDC 69315016101) is labeled by Leading Pharma, LLC, and CMS classifies it as a generic product.